THE ADMINISTRATORS OF TULANE EDUCATIONAL FUND

• UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  UEI MKAGLD59JRL1

  $1.2M

  Subcontractor to this prime · 2 sub-awards · latest Mar 21, 2025

  • Defense Health Agency
  • “PREHOSPITAL AIRWAY CONTROL TRIAL BASE AWARD”
  • “THE AIMS OF THE CALCIUM AND VASOPRESSIN POST-INJURY EARLY RESUSCITATION (CAVALIER) TRIAL ARE TO DETERMINE THE SAFETY AND EFFICACY OF PREHOSPITAL CALCIUM SUPPLEMENTATION AND EARLY IN-HOSPITAL VASOPRESSIN INFUSION AS COMPARED TO STANDARD CARE RESUSCITATION IN PATIENTS AT RISK OF HEMORRHAGIC SHOCK AND TO APPROPRIATELY CHARACTERIZE ANY ADDITIVE EFFECT OF BOTH RESUSCITATION ADJUNCT INTERVENTIONS. CAVALIER'S PRIMARY STUDY OBJECTIVE IS TO DETERMINE WHETHER PREHOSPITAL CALCIUM, EARLY IN-HOSPITAL VASOPRESSIN, OR BOTH AS COMPARED TO PLACEBO RESULTS IN LOWER 30-DAY MORTALITY IN PATIENTS AT RISK OF HEMORRHAGIC SHOCK. SECONDARY STUDY OBJECTIVES INCLUDE DETERMINING WHETHER THE INTERVENTIONS ARE ASSOCIATED WITH MORTALITY OUTCOMES (6-HOUR, 24-HOUR, IN-HOSPITAL, DEATH FROM HEMORRHAGE AND BRAIN INJURY), BLOOD AND BLOOD COMPONENT TRANSFUSION REQUIREMENTS (6- HOUR AND 24-HOUR), INCIDENCE OF MULTIPLE ORGAN FAILURE (MOF), INCIDENCE OF NOSOCOMIAL INFECTION, TIME TO HEMOSTASIS, INCIDENCE OF COAGULOPATHY BY THROMBOELASTOGRAPHY (TEG), AND ICU-FREE AND HOSPITAL-FREE DAYS.”

• SCRIPPS RESEARCH INSTITUTE

  UEI PHZJFZ32NKH4

  $687.5K

  Subcontracted by this company · 1 sub-award · latest Oct 22, 2024

  • National Institutes of Health
  • “THE SUBCONTRACTOR LAB WILL HELP COLLEAGUES WITH THE PRODUCTION, PURIFICATION, AND CHARACTERIZATION OF THE IMMUNOGENS FOR THE STUDY, INCLUDING THE REAGENTS NEEDED FOR ELISA AND BIOLAYER INTERFEROMETRY ASSAYS (BLI) TO ASSESS ANTIBODY AFFINITY, AND VIRUSES TO BE TESTED FOR TZM-BL HIV-1 NEUTRALIZATION ASSAY. WE WILL ALSO PROVIDE THE REAGENTS AND SUPPLIES NEEDED FOR ANTIGEN SPECIFIC B CELL SORTING TO OBTAIN AND GENERATE ENV-SPECIFIC B CELL CLONES AND WITH A FOCUS ON IDENTIFYING CLONES TARGETING ENV FUSION PEPTIDE. WE WILL SCREEN ANIMALS FOR VIRUS SPECIFIC RESPONSES AND ASSESS BINDING SITES TO ASSESS SPECIFICITY AND BREADTH OF PROTECTION”
• Q-VANT BIOSCIENCES, INC.

  UEI HDX6GCQFFD77

  $381.2K

  Subcontracted by this company · 1 sub-award · latest May 8, 2026

  • National Institutes of Health
  • “Q-VANT BIOSCIENCES, INC. WILL BE A KEY PARTNER BY PROVIDING ALL THE SAPONIN ADJUVANTS FOR THESE STUDIES AND BY PROVIDING FDA REGULATORY AND PRE-IND SUPPORT. THIS INCLUDES TYPE-2 GRADE SAPONINS AND QS-21 ADJUVANTS FOR TESTING IN MILESTONE (1), METHODS FOR EVALUATING DUAL POTENCY (MILESTONE 2), AND PURIFICATION OF GLP/GMP GRADE SAPONIN ADJUVANTS AND PRE-IND MEETING PREPARATIONS FOR SDS (MILESTONE 3 STUDIES).”
• PATH

  UEI PD3VNAABZJL7

  $305.9K

  Subcontracted by this company · 1 sub-award · latest Apr 1, 2026

  • National Institutes of Health
  • “PATH'S PROPOSED SCOPE OF WORK UNDER THIS SUBCONTRACT IS TO SUPPORT THE DEVELOPMENT OF COMBINATION ADJUVANTS SAPONIN AND DMLT FOR ORAL DELIVERY.”

No active exclusion on record (checked Nov 14, 2026).

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.